Kymera Therapeutics Inc   (KYMR)
Other Ticker:  

The Top-line plunged at the company during the financial time-frame closing Sep 30 2022

company recorded third quarter of 2022 operating shortfall of $-44.882 millions

Published 2022-11-06T04:53:19+00:00
Goran Soko / CSIMarket.com Contributer

closeup_By_Jean-Etienne_Minh-Duy_Poirrier_from_Bruxelles_Belgium_[CC-BY-SA-2.0_(http_creativecommons.org_licenses_by-sa_2.0)]_via_Wikimedia_CommonsFor the financial period ending September 30 2022 company increased a deficit per share of $-0.79 per share compare to $-0.55 a year ago and surged deficit from $-0.78 per share from the prior financial reporting period.

Revenues faded by -48.426 % to $9.55 millions from $18.52 millions in the similar financial reporting period a year ago and sequentially Revenues fell by -17.049 % from $11.51 millions.

For the financial period ending September 30 2022 Kymera Therapeutics Inc realized net deficit of $-43.002 million, larger than $-24.660 million a year ago.

Kymera Therapeutics Inc is expected to report next financial results on February 23, 2023.

    Recently Reported Results